Asthma Market Research Reports & Industry Analysis
The strongest risk factors for developing asthma are a person’s exposure to allergens and a family history of asthma or allergy. Exposure to tobacco smoke and exposure to chemical irritants in the workplace are additional risk factors. Workplace conditions, such as exposure to fumes, gases or dust, are responsible for 11% of asthma cases worldwide.
Asthma Industry Research & Market Reports
-
Global Asthma Partnering 2012 to 2018
... in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agreements entered into by ... Read More
-
Global COPD Partnering 2012 to 2018
... in partnering deals • Top deals by value • Deals listed by company A-Z, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agreements entered into by ... Read More
-
The 2019-2024 Outlook for Asthma Therapeutics in the United States
... U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the ... Read More
-
The 2019-2024 Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations in the United States
... the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the ... Read More
-
The 2019-2024 Outlook for Asthma Treatments in the United States
... U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the ... Read More
-
The 2019-2024 Outlook for Local and Topical Corticoids, Hormones, and Synthetic Hormone Substitute Pharmaceuticals in the United States
... substitute pharmaceuticals across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For ... Read More
-
Global COPD Therapeutics Market Research Report 2018
... focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications ... Read More
-
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018
... of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape. Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading ... Read More
-
Asthma - Pipeline Review, H1 2018
... a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing ... Read More
-
Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]
... biologics and new MOAs as the COPD treatment landscape continues to evolve. Of the key companies currently competing in this space -- AstraZeneca, Boehringer Ingelheim, GSK and Novartis -- which companies do key opinion leaders ... Read More
-
Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]
... IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial ... Read More
-
COPD: KOL Insight
... the COPD treatment landscape continues to evolve. Of the key companies currently competing in this space -- AstraZeneca, Boehringer Ingelheim, GSK and Novartis -- which companies do key opinion leaders (KOLs) think will take the ... Read More
-
Asthma Treatment Drugs Markets in China
... The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines ... Read More
-
Asthma Treatment Drugs Industry Forecasts - China Focus
... expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in ... Read More
-
Asthma Treatment Drugs Companies in China
... dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies ... Read More
-
Global Oxymetry Market Report and Forecast to 2022
... focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China). In this report, the global Oxymetry market is valued at USD XX ... Read More
-
Global Oxymetry Market Size and Forecast to 2022
... focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom,Japan, South Korea and China). In this report, the global Oxymetry market is valued at USD XX ... Read More
-
Respiratory Drugs Global Market Outlook 2018 Including: Respiratory Drugs, Anti-Asthmatics And COPD Drugs, Decongestants, Cough And Cold Preparations.Covering: GlaxosmithKline Plc., AstraZeneca Plc., Merck & Co., Novartis AG, Johnson & Johnson, Gilead, Ba
... Ingelheim GmbH, Teva Pharmaceuticals, Pfizer Inc. North America was the largest region in the respiratory diseases drugs market in 2017, accounting for around 48% market share. Asia Pacific was the second largest region accounting for ... Read More
-
Novel Drugs and Smart Devices for Respiratory Disorders, 2018 - 2030
... chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. Specifically, COPD is currently known to be the fourth leading cause of death worldwide. ... Read More
-
Respiratory Diseases Drugs Global Market Report 2018 Including: Anti-Asthmatics And COPD Drugs; Cough And Cold PreparationsCovering: GlaxosmithKline Plc,AstraZeneca Plc,Merck & Co,Novartis AG,Johnson & Johnson
... Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global respiratory diseases drugs market. Reasons to Purchase Outperform competitors using accurate up to date demand-side dynamics ... Read More
-
The 2019-2024 World Outlook for Bronchial Dilator and Anti-Asthmatic Pharmaceutical Preparations
... are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These ... Read More
-
The 2019-2024 World Outlook for Asthma Treatments
... industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge ... Read More
-
The 2019-2024 World Outlook for Asthma Therapeutics
... industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge ... Read More
-
The 2019-2024 World Outlook for Asthma and Chronic Obstructive Pulmonary Disease (COPD) Therapies
... each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and ... Read More
-
Targeted Therapies in Asthma: KOL Insight [2018]
... to use currently approved treatments, including Xolair, Nucala and Cinqair/Cinqaero, and which treatments offer the best for patients. Visible on the horizon is another anti-IL-5 mAb, AstraZeneca’s Fasenra (benralizumab), and by all accounts KOLs believe ... Read More
